Sienna Biopharmaceuticals, Inc. (SNNA) financial statements (2022 and earlier)

Company profile

Business Address 30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments48,52674,467
Cash and cash equivalents48,52674,467
Restricted cash and investments181181
Other undisclosed current assets1,7052,698
Total current assets:50,41277,346
Noncurrent Assets
Property, plant and equipment311432
Intangible assets, net (including goodwill)10,98911,472
Goodwill10,98911,472
Other undisclosed noncurrent assets45,59447,597
Total noncurrent assets:56,89459,501
TOTAL ASSETS:107,306136,847
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,6368,010
Accounts payable2,7922,357
Accrued liabilities4,7873,007
Employee-related liabilities3,0572,646
Business combination, contingent consideration, liability13,500 
Other undisclosed current liabilities213231
Total current liabilities:24,3498,241
Noncurrent Liabilities
Long-term debt and lease obligation30,125 
Long-term debt, excluding current maturities30,125 
Liabilities, other than long-term debt26,20333,864
Deferred tax liabilities, net10,50310,964
Business combination, contingent consideration, liability15,70022,900
Other undisclosed noncurrent liabilities483,543
Total noncurrent liabilities:56,37637,407
Total liabilities:80,72545,648
Stockholders' equity
Stockholders' equity attributable to parent26,58191,199
Common stock 2
Additional paid in capital182,750171,724
Accumulated other comprehensive income3,1995,370
Accumulated deficit(159,368)(85,897)
Total stockholders' equity:26,58191,199
TOTAL LIABILITIES AND EQUITY:107,306136,847

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
Operating expenses(76,498)(48,571)
Operating loss:(76,498)(48,571)
Nonoperating income (expense)3,027(2,264)
Loss from continuing operations before income taxes:(73,471)(50,835)
Income tax benefit 290
Net loss available to common stockholders, diluted:(73,471)(50,545)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
Net loss:(73,471)(50,545)
Other comprehensive loss(2,171) 
Comprehensive loss:(75,642)(50,545)
Other undisclosed comprehensive income, net of tax, attributable to parent 5,736
Comprehensive loss, net of tax, attributable to parent:(75,642)(44,809)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: